NSAIDs are the most widely used drugs globaly and are very famous for
their analgesic, anti-in- flammatory and antipyretic actions. The use of NSAIDs
in a variety of cancerous conditions is also approved now because of its
versatile pharmacologic actions. In this research based study the use of NSAIDs
as a chemointerceptive agent in a variety of cancers has been discussed. We
aimed to know about the chemopreventive effects of NSAIDs that are a very
diverse group of drugs having a lot of pharmacological actions. Now they are
advised to prevent from various types of cancers by its different mechanisms
and processes like inhibition of angiogenesis, COX-2 and it potentiates the
process of apoptosis which is also a very favourable point for NSAIDs to work
as a chemointerceptive agent. Heeding to the results aspirin could intercept
from cancer (37%) and other NSAIDs used as acheminterceptive agents (28%). All of
the NSAIDs have less side effects as compared to the drugs that are used during
chemotherapy. The inhibition of COX-1 enzyme by NSAIDs is (15%) and that of COX-2 (85%). Studies suggested that the most
frequent cancer in males is 14.5% of colorectal cancer and 10% prostate
cancer while in female the most common cancers are 27% of breast cancer and 15%
of colorectal cancer. 30% of ovarian cancer is also very common in many females
of elder age groups. It was concluded that NSAIDs are a diverse group of drugs
and advised to manipulate as a chemointerceptive agents in a variety of
cancers. Besides these studies there are many limitations heeding to the
chronic usage of NSAIDs, which should also be considered. The use of NSAIDs as
a chemointerceptive agent requires more further experimental studies and needs
clinical trials.
Cite this paper
Ayub, M. and Islam, A. (2015). Prevalence of Nsaids (Non Steroidal Inflammatory Drugs) as a Chemopreventive Agent in Different Types of Cancer: Retrospective Detail Studies. Open Access Library Journal, 2, e1830. doi: http://dx.doi.org/10.4236/oalib.1101830.
GLOBOCAN 2012 v1.0 (2013) Cancer Incidence and Mortality Worldwide: IARC
CancerBase No.
11 [database on the Internet]. International Agency for Research on Cancer. http://globocan.iarc.fr
Pohl, H.
and Welch, H.G. (2005) The Role of Overdiagnosis and Reclassification in
the Marked Increase of Esophageal Adenocarcinoma Incidence. Journal of the National Cancer Institute, 97, 142-146. http://dx.doi.org/10.1093/jnci/dji024
Pohl, H., Sirovich, B.
and Welch, H.G. (2010) Esophageal Adenocarcinoma Incidence: Are We
Reaching the Peak? Cancer Epidemiology, Biomarkers & Prevention, 19, 1468-1470. http://dx.doi.org/10.1158/1055-9965.EPI-10-0012
Thrift, A.P.
and Whiteman, D.C. (2012) The Incidence of Esophageal Adenocarcinoma
Continues to Rise: Analysis of Period and Birth Cohort Effects on Recent Trends. Annals of Oncology, 23, 3155-3162. http://dx.doi.org/10.1093/annonc/mds181
Engel, L.S., Chow, W.-H., Vaughan, T.L., et al. (2003) Population
Attributable Risks of Esophageal and Gastric Cancers. Journal of the National Cancer Institute, 95, 1404-1413. http://dx.doi.org/10.1093/jnci/djg047
Pandeya, N.,
Olsen, C.M. and Whiteman, D.C. (2013) Sex Differences in the Proportion of Esophageal
Squamous Cell Carcinoma Cases Attributable to Tobacco Smoking and Alcohol
Consumption. Cancer Epidemiology, 37, 579-584.
Howlader, N., Noone, A., Krapcho, M., et al.
(2014) SEER
Cancer Statistics Review, 1975-2011. National Cancer Institute. Bethesda, MD. (Based
on November 2013 SEER data submission, posted to the SEER web site, April 2014) http://seer.cancer.gov/csr/1975_2011/
Cook, M.B.,
Chow, W.H. and Devesa, S.S. (2009) Oesophageal
Cancer Incidence in the United States by Race, Sex, and Histologic Type,
1977-2005. British Journal of Cancer, 101, 855-859. http://dx.doi.org/10.1038/sj.bjc.6605246
Dubecz, A., Gall, I., Solymosi, N., Schweigert, M., Peters, J.H., Feith, M.
and Stein, H.J.
(2012) Temporal Trends in Long-Term Survival and Cure
Rates in Esophageal Cancer: A SEER Database Analysis. Journal of Thoracic Oncology, 7, 443-447. http://dx.doi.org/10.1097/jto.0b013e3182397751
Ronkainen, J., Aro, P., Storskrubb, T., Johansson,
S.E., Lind, T., Bolling-Sternevald, E., et al. (2005) Prevalence of Barrett’s Esophagus in the General Population: An
Endoscopic Study. Gastroenterology, 129, 1825-1831. http://dx.doi.org/10.1053/j.gastro.2005.08.053
Kendall, B.J.
and Whiteman, D.C.
(2006) Temporal Changes in the Endoscopic Frequency of
New Cases of Barrett’s Esophagus in an Australian Health Region. The American Journal of Gastroenterology, 101, 1178-1182. http://dx.doi.org/10.1111/j.1572-0241.2006.00548.x
Krishnan, K., Ruffin IV,
M.T. and Brenner, D.E. (2000) Chemoprevention for Colorectal Cancer. Critical Reviews in Oncology/Hematology, 33, 199-219. http://dx.doi.org/10.1016/S1040-8428(99)00075-X
Shiff, J.S. and Rigas, B. (1997) Nonsteroidal Anti-Inflammatory Drugs and
Colorectal Cancer: Evolving Concepts of Their Chemopreventive Actions. Gastroenterology, 113, 1992-1998. http://dx.doi.org/10.1016/S0016-5085(97)99999-6
Shiff, J.S. and Rigas, B. (1999) The Role of Cyclooxygenase Inhibition in the
Antineoplastic Effects of Nonsteroidal Anti-Inflammatory Drugs. The Journal of Experimental Medicine, 190, 445-450. http://dx.doi.org/10.1084/jem.190.4.445
Bjorkman, D.J. (1999) Current Status of Nonsteroidal
Anti-Inflammatory Drug (NSAID) Use in the United States: Risk Factors and
Frequency of Complications. American
Journal of Medicine, 107, 3S-8S.
Del Soldato, P., Sorrentino, R. and Pinto,
A. (1999) NO-Aspirins: A Class of New Anti-Inflammatory and Antithrombotic Agents. Trends in Pharmacological Sciences, 20, 319-323. http://dx.doi.org/10.1016/S0165-6147(99)01353-X
Wolfe, M.M. (1998) Future Trends in the Development of Safer
Nonsteroidal Anti-Inflammatory Drugs. American
Journal of Medicine, 105, 44S-52S. http://dx.doi.org/10.1016/S0002-9343(98)00281-2
Fiorucci, S.,
Antonelli, E., Santucci, L., Morelli, O., Miglietti, M., Federici, B.,
Mannucci, R., Del Soldato, P. and Morelli, A. (1999) Gastrointestinal Safety of Nitric Oxide-Derived Aspirin Is Related to
Inhibition of ICE-Like Cysteine Proteases in Rats. Gastroenterology, 116, 1089-1106. http://dx.doi.org/10.1016/S0016-5085(99)70012-0
Qiao, L., Hanif, R., Sphicas, E., Shiff, S.J.
and Rigas, B. (1998) Effect of Aspirin on Induction of Apoptosis in HT-29 Human Colon Adenocarcinoma
Cells. Biochemical Pharmacology, 55, 53-64. http://dx.doi.org/10.1016/S0006-2952(97)00400-0
Shiff, S.J., Koutsos, M.I., Qiao, L. and Rigas, B. (1996) Nonsteroidal Anti-Inflammatory Drugs Inhibit the Proliferation of Colon
Adenocarcinoma Cells: Effects on Cell Cycle and Apoptosis. Experimental Cell Research, 222, 179-188. http://dx.doi.org/10.1006/excr.1996.0023
Hanif, R., Feng, J., Shiff, S.J., Koutsos,
M.I., Staiano-Coico, L. and Rigas, B. (1996) NSAIDs Inhibit the Growth of Colon Cancer Cells
by a Prostaglandin-Independent Pathway. Biochemical
Pharmacology, 52, 237-245. http://dx.doi.org/10.1016/0006-2952(96)00181-5
Rigas, B. and Shiff, S.J. (2000) Is an Effect on Cyclooxygenase Required for the Chemopreventive Effect
of NSAIDs in Colon Cancer? A Model Reconciling the Current Contradiction. Medical Hypotheses, 54, 210-215. http://dx.doi.org/10.1054/mehy.1999.0023
Bakm, A.W., McKnight, W., Li, P., Del Soldato,
P., Calignano, A., Cirino, G. and Wallace, J.L. (1998) Cyclooxygenase-Independent Chemoprevention with
an Aspirin Derivative in a Rat Model of Colonic Adenocarcinoma. Life Sciences, 62, 367-373. http://dx.doi.org/10.1016/S0024-3205(98)00191-X
Garcia-Rodriguez, L.A. and Huerta-Alvarez, C. (2001) Reduced Risk of Colorectal Cancer among
Long-Term Users of Aspirin and Non-Aspirin Nonsteroidal Anti-Inflammatory
Drugs. Epidemiology, 12, 88-93. http://dx.doi.org/10.1097/00001648-200101000-00015
Rosenberg, L., Palmer, J.R., Zauber, A.G.,
Warshauer, M.E., Stolley, P.D. and Shapiro, S. (1991) A Hypothesis: Nonsteroidal Anti-Inflammatory Drugs Reduce the Incidence of Large
Bowel Cancer. Journal of the National
Cancer Institute, 83, 355-358. http://dx.doi.org/10.1093/jnci/83.5.355
Giovannucci, E., Rim,
E.B., Stampfer, M.J., Colditz, G.A., Ascherio, A. and Willett, W.C. (1994) Aspirin Use and the Risk of Colorectal Cancer
and Adenoma in Male Health Professionals. Annals
of Internal Medicine, 121, 241-246. http://dx.doi.org/10.7326/0003-4819-121-4-199408150-00001
Giovannucci, E., Egan, K., Hunter, D.J., Stampfer, M.J., Colditz,
G.A., Ascherio, A., Willett, W.C. and Speizer, F.E. (1995) Aspirin and the Risk of Colorectal Cancer in
Women. The New England Journal of
Medicine, 333, 609-614. http://dx.doi.org/10.1056/NEJM199509073331001
Thun, M.J., Namboodiri, M.M. and Heath Jr.,
C.W. (1991) Aspirin Use and Reduced Risk of Fatal Colon Cancer. The New England Journal of Medicine, 325, 1593-1596. http://dx.doi.org/10.1056/NEJM199112053252301
Pollard, M. and Luckert, P.H. (1980) Indomethacin Treatment of Rats with Dimethylhydrazine-Induced Intestinal
Tumors. Cancer Treatment Reviews, 64, 1323-1327.
Pollard,
M. and Luckert, P.H. (1984) Effect of Piroxicam on Primary Intestinal
Tumors Induced in Rats by N-Methylnitrosourea. Cancer Letters, 25, 117-121. http://dx.doi.org/10.1016/S0304-3835(84)80035-X
Metzger, U., Meier, J., Uhlshmid, G. and
Weihe, H. (1984) Influence of Various Prostaglandin Synthesis Inhibitors on DMH-Induced
Rat Colon Cancer. Diseases
of the Colon & Rectum, 27, 366-369. http://dx.doi.org/10.1007/BF02553001
Reddy, B.S.,
Maruyama, H. and Kelloff, G. (1987) Dose-Related Inhibition of Dietary Piroxicam, a Nonsteroidal Anti- Inflammatory
Drug, during Different Stages of Rat Colon Tumor Development. Cancer Research, 47, 5340-5346.
Reddy, B.S., Nayini, J., Tokumo, K., Rigotty, J.,
Zang, E. and Kelloff, G. (1990) Chemoprevention of
Colon Carcinogenesis by Concurrent Administration of Piroxicam, a
Nonsteroidal Anti-Inflammatory Drug with D,L-a-diftuoromethylor- nithine, an Ornithine Decarboxylase Inhibitor, in Diet. Cancer Research, 50, 2562-2568.
Takahashi, M., Furukawa, F., Toyoda, K., Sato,
H., Hasegawa, R., Imaida, K. and Hayashi, Y. (1990) Effects of Various Prostaglandin Synthesis Inhibitors
on Pancreatic carcinogenesis in Hamsters after Initiation with N-Nitrosobis(2- oxopropyl)amine. Carcinogenesis, 11, 393-395. http://dx.doi.org/10.1093/carcin/11.3.393
Tanaka, T.,
Kojima, T., Okumura, A., Sugie, S. and Mori, H. (1993) Inhibitory Effect of the Non-Steroidal Anti- Inflammatory Drugs, Indomethacin and Piroxicam on
2-Acetylaminofluorene-Induced Hepatocarcinogenesis in Male ACI/N Rats. Cancer Letters, 68, 111-118. http://dx.doi.org/10.1016/0304-3835(93)90136-W
Jalbert, G. and Castonguay, A. (1992) Effects of NSAIDs on NNK-Induced Pulmonary and Gastric Tumorigenesis in
A/J Mice. Cancer Letters, 66, 21-28. http://dx.doi.org/10.1016/0304-3835(92)90275-Z
Thun, M.S.,
Namboodiri, M.M., Calle, E.E., Flanders, M.D. and Heath Jr., C.W. (1993) Aspirin Use and Risk of Fatal Cancer. Cancer Letters, 53, 1322-1327.
Gridley, G.,
McLaughlin, J.K., Ekbom, A., Klareskog, L., Adami, H.O., Hacker, D.G., Hoover,
R. and Fraumeni, J.F. (1993) Incidence of Cancer among Patients with Rheumatoid
Arthritis. Journal of the National Cancer
Institute, 85, 307-311. http://dx.doi.org/10.1093/jnci/85.4.307
Schreinemachers, D.M. and Everson, R.B. (1994) Aspirin Use and Lung, Colon, and Breast Cancer
Incidence in a Prospective Study. Epidemiology, 5, 138-146.
Flegal, K.M., Carroll, M.D., Kit, B.K.
and Ogden, C.L.
(2012) Prevalence of Obesity and Trends in the Distribution of Body Mass Index among US Adults, 1999-2010. The Journal of the American Medical Association, 307, 491-497. http://dx.doi.org/10.1001/jama.2012.39
Calle, E.E.,
Rodriguez, C.,
Walker-Thurmond, K. and Thun, M.J. (2003) Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of US Adults. The New England Journal of Medicine, 348, 1625-1638. http://dx.doi.org/10.1056/NEJMoa021423
